Amezcua-Macías A, Rodríguez-Weber FL, Juan Díaz-Greene E

Language: Spanish
References: 18
Page: 274-280
PDF size: 278.79 Kb.

ABSTRACT

Objectives: To determine the degree of adherence to the treatment in patients with diabetes type 2 as well as the adherence to the treatment of the comorbidities most frequently associated, such as arterial hypertension, hyperlipidemia and obesity; to identify the possible causes of noncompliance to the treatments, to make statistical treatment of the data, to analyze and to discuss the results of the study.
Material and method: A monocentric, longitudinal, observational and analytical study was made in patients older than 18 years, with diabetes mellitus type 2 with more than six months of diagnosis with or without comorbidities, such as arterial hypertension, hyperlipidemia and obesity, that assisted to external consultation of Internal Medicine of a health center in Mexico City. Patients with diagnosis lower than six months were excluded, as well as those with co-morbidities that influence the adherence to the treatment, such as chronich obstructive pulmonary disease, hyper-hypothyroidism and cerebral vascular disease, among others.
Results: Twenty-two controlled patients and 33 not-controlled patients were included; of the diabetic controlled patients, 11 had good adherence, 4 had regular adherence and 7 had bad adherence to the treatment; of the 33 diabetic not-controlled patients, 10 had good adherence, 18 had regulate adherence and 5 had bad adherence to the treatment, being the main cause of noncompliance the economic factor.
Conclusions: According to established goals, we found that some patients reached the goals without having a proper adherence to treatment; however, those patients represent the minority, because most patients had regular and good adherence to treatment.

REFERENCES

1. Durán Varela BR, Rivera Chavira B, Franco Gallegos E. Apego al tratamiento farmacológico en pacientes con diagnóstico de diabetes mellitus tipo 2. Salud Pública Méx 2001;43:233-236.

2. Mejía J, Carmona F. Abandono al tratamiento antitubeculoso. Factores asociados. Rev Med Inst Seguro Soc 1995;33:481-485.

3. Martínez MC, Guiscafré H, Muñoz O, Gutiérrez G. Análisis del cumplimiento del tratamiento en los esquemas terapéuticos utilizados. Arch Invest Med Mex 1988;19:409-417.

4. Mason B, Matsuyama J, Jue S. Adherence consistency across treatment regimens. Latter Diabetes Care 1994;44:235-240.

5. Ortiz-Domínguez ME, Garrido-Latorre F, Orozco R, Pineda-Pérez D, Rodríguez-Salgado M. Sistema de Protección Social en Salud y calidad de la atención de hipertensión arterial y diabetes mellitus en centros de salud. Salud Pública Méx 2011;53:436-444.

6. American Diabetes Association. Standards of Medical Care in Diabetes 2013, Diabetes Care, Volumen 36, Supplement 1, January 2013, The JNC 7 Report. JAMA 2003;289:2560-2572, Adult Treatment Panel III (ATP III). JAMA 2001;285:2486-2497.

7. The JNC 7 Report. JAMA 2003;289:2560-2572.

8. Adult Treatment Panel III (ATP III). JAMA 2001;285:2486-2497

9. Encuesta Nacional de Salud y Nutrición 2012 (ENSANUT).

10. World Health Organization, diabetes mellitus fact sheet, 2002;238. [Accessed august 13, 2006].

11. Kuo YF, Raji MA, Markides KS, Ray LA, et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054-3060.

12. van Bruggen R, Gorter K, Stolk RP, Zuithoff P, et al. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 2009;18:983-991.

13. Turner RC, Cull CA, Fright V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA 1999;281:2005-2012.

14. Yusuff KB, Obe O, Joseph BY. Adherence to antidiabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Scl 2008;30:876-883.

15. Flores HS, et al. Diabetes en adultos; urgente mejorar la atención y el control. INSP. ENSANUT 2012.

16. VázquezF, Arreola F, Castro G, Escobedo J, y col. Aspectos psicosociales de la diabetes mellitus. Rev Med Inst Mex Seguro Soc 1994;32:267-270.

17. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent in-crease in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006;29:2114-2116.

18. Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, et al. Medication nonadherence in diabetes longitudinal effects on costs and potential cost savings from improvement: Diabetes Care 2012;35:2533-2539.